In terms of revenue, global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Size was valued at US$ 1217.34 Mn in 2020 and is anticipated to reach US$ 2052.93 Mn by 2030 growing at a CAGR of 6.0% over the forecast period (2021 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

The alpha1 antitrypsin deficiency (AATD) is a hereditary disorder. This disorder is characterized by a lack or deficiency of alpha1 antitrypsin in the blood, a protein that is important for the proper and healthy functioning of the lungs. The respiratory deficiency was first identified by Carl-Bertil Laurell and Sten Eriksson (Laurell and Eriksson 1963) in 1963. They discovered a link between low plasma serum AAT levels and pulmonary emphysema symptoms. As the understanding of the genetic abnormalities grew with time, AAT deficiency came to be recognized as one of the most common hereditary disorders globally. The alpha1-antitrypsin deficiency (AATD) therapy involves extracting AAT protein from a healthy donor’s blood plasma for increasing AAT levels in the respiratory tract of patients. This treatment has also been found to delay the progression of emphysema, minimize the frequency of exacerbations and improve recovery speed, a factor that has led to its increasing preference among both the patients and healthcare providers. Hence, the increasing prevalence of respiratory disorders is one of the key factors driving the growth of the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Moreover, efficient distribution of augmentation therapy drugs by leading manufacturers is also found to be propelling the market growth with a remarkable rate.

Access the Full Report @

Recent advancements in diagnostic tools for genetic diseases have made revolutionary progress in the diagnosis and treatment of AATD. Patients with AATD require regular regimented care, for which augmentation therapy is specifically preferred treatment option. Hence, improved diagnostic techniques for genetic disorders, coupled with rising prevalence of AATD are significantly boosting the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Moreover, manufacturers and researchers are also currently striving to find effective ways to provide the therapy with more flexibility in their treatment regimen. Various established pharmaceutical players such as Biocerna LLC and Octapharma are engaged in conducting research on new and existing molecules for the betterment of AATD treatment scenario.

Some of the players operating in the global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Size are Abeona Therapeutics Inc., Baxter, CSL, Grifols, S.A., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, and other market participants.

The report provides both, qualitative and quantitative research of global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market

By End-User

  • Hospitals and Clinics
  • Physicians Office
  • Outpatient Infusion Centers
  • Others

By Application

  • Emphysema
  • Alpha-1
  • Others

By Recommended Dose

  • 60 mg/kg IV (Weekly)
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific 
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna